Overview
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Description
Whole blood, plasma, and/or serum specimens will be collected from patients with active cancer, patients in cancer remission, patients diagnosed with benign disease, and healthy volunteers. These blood samples will be used to perform various studies to determine the utility of select DNA methylation markers for cancer diagnostic or prognostic indications.
Eligibility
Inclusion Criteria:
2.1.1 Age 18 years or older.
2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes,
liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive
pulmonary disease, etc.) or apparently healthy volunteers. .
Exclusion Criteria:
2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be
excluded.
2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period
under this protocol. Patients that have already given 50 mL of blood within this time frame
will be excluded.